Houman Ashrafian

Houman Ashrafian

Auto-generated profile, based on publicly available information

Houman Ashrafian

Division of Cardivascular Medicine, Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research, Oxford, UK

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2007 in Circulation
Verified
Journal Article
Closed access
HAHouman Ashrafian
Houman Ashrafian
MFMichael P. Frenneaux
Michael P. Frenneaux
LOLionel H. Opie
Lionel H. Opie
Although neurohumoral antagonism has successfully reduced heart failure morbidity and mortality, the residual disability and death rate remains unacceptably high. Though abnormalities of myocardial metabolism are associated with heart failure, recent data suggest that heart failure may itself promote metabolic changes such as insulin resistance, in part through neurohumoral activation. A detrimental self-perpetuating cycle (heart failure → altered metabolism → heart failure) that promotes the progression of heart failure may thus be postulated. Accordingly, we review the cellular mechanisms and pathophysiology of altered metabolism and insulin resistance in heart failure. It is hypothesized that the ensuing detrimental myocardial energetic perturbations result from neurohumoral activation, increased adverse free fatty acid metabolism, decreased protective glucose metabolism, and in some cases insulin resistance. The result is depletion of myocardial ATP, phosphocreatine, and creatine kinase with decreased efficiency of mechanical work. On the basis of the mechanisms outlined, appropriate therapies to mitigate aberrant metabolism include intense neurohumoral antagonism, limitation of diuretics, correction of hypokalemia, exercise, and diet. We also discuss more novel mechanistic-based therapies to ameliorate metabolism and insulin resistance in heart failure. For example, metabolic modulators may optimize myocardial substrate utilization to improve cardiac function and exercise performance beyond standard care. The ultimate success of metabolic-based therapy will be manifest by its capacity further to lessen the residual mortality in heart failure.

28 April 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
HWHugh Watkins
Hugh Watkins
HAHouman Ashrafian
Houman Ashrafian
CRCharles Redwood
Charles Redwood
Inherited cardiomyopathies are a major cause of heart disease in all age groups, often with an onset in adolescence or early adult life. Not only the patients but also their families can be severely burdened by these illnesses. More than 20 years ago, the first “disease gene” for hypertrophic cardiomyopathy was identified.1,2 This finding led to the concept that hypertrophic cardiomyopathy is a disease of the sarcomere.3 Similar advances in the elucidation of the genetic basis of other forms of cardiomyopathy, as well as in other inherited cardiovascular diseases, soon followed.

1 May 2003 in Trends in Genetics
Verified
Journal Article
Closed access
HAHouman Ashrafian
Houman Ashrafian
CRCharles Redwood
Charles Redwood
EBEdward Blair
Edward Blair
HWHugh Watkins
Hugh Watkins

22 November 2005 in Circulation
Verified
Journal Article
Closed access
LLLeong Lee
Leong Lee
RCRoss Campbell
Ross Campbell
MSMichaela Scheuermann-Freestone
Michaela Scheuermann-Freestone
RTRachel Taylor
Rachel Taylor
PGPrasad Gunaruwan
Prasad Gunaruwan
MFMichael Frenneaux
Michael Frenneaux
Background— Chronic heart failure (CHF) is a major cause of morbidity and mortality that requires a novel approach to therapy. Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We assessed the effects of perhexiline treatment in CHF patients. Methods and Results— In a double-blind fashion, we randomly assigned patients with optimally medicated CHF to either perhexiline (n=28) or placebo (n=28). The primary end point was peak exercise oxygen consumption (V̇ o 2 max), an important prognostic marker. In addition, the effect of perhexiline on myocardial function and quality of life was assessed. Quantitative stress echocardiography with tissue Doppler measurements was used to assess regional myocardial function in patients with ischemic CHF. 31 P magnetic resonance spectroscopy was used to assess the effect of perhexiline on skeletal muscle energetics in patients with nonischemic CHF. Treatment with perhexiline led to significant improvements in V̇ o 2 max (16.1±0.6 to 18.8±1.1 mL · kg −1 · min −1 ; P <0.001), quality of life (Minnesota score reduction from 45±5 to 34±5; P =0.04), and left ventricular ejection fraction (24±1% to 34±2%; P <0.001). Perhexiline treatment also increased resting and peak dobutamine stress regional myocardial function (by 15% and 24%, respectively) and normalized skeletal muscle phosphocreatine recovery after exercise. There were no adverse effects during the treatment period. Conclusions— In patients with CHF, metabolic modulation with perhexiline improved V̇ o 2 max, left ventricular ejection fraction, symptoms, resting and peak stress myocardial function, and skeletal muscle energetics. Perhexiline may therefore represent a novel treatment for CHF with a good safety profile, provided that the dosage is adjusted according to plasma levels.

1 July 2009 in JACC
Verified
Journal Article
Closed access
TPThanh T. Phan
Thanh T. Phan
KAKhalid Abozguia
Khalid Abozguia
GSGanesh Nallur Shivu
Ganesh Nallur Shivu
GMGnanadevan Mahadevan
Gnanadevan Mahadevan
IAIbrar Ahmed
Ibrar Ahmed
MFMichael Frenneaux
Michael Frenneaux

19 October 2010 in Circulation
Verified
Journal Article
Closed access
KAKhalid Abozguia
Khalid Abozguia
Perry ElliottPerry Elliott
Perry Elliott
WMWilliam McKenna
William McKenna
TPThanh Trung Phan
Thanh Trung Phan
GNGanesh Nallur-Shivu
Ganesh Nallur-Shivu
MFMichael Frenneaux
Michael Frenneaux
Background—: Hypertrophic cardiomyopathy patients exhibit myocardial energetic impairment, but a causative role for this energy deficiency in the pathophysiology of hypertrophic cardiomyopathy remains unproven. We hypothesized that the metabolic modulator perhexiline would ameliorate myocardial energy deficiency and thereby improve diastolic function and exercise capacity. Methods and Results—: Forty-six consecutive patients with symptomatic exercise limitation (peak V̇ o 2 <75% of predicted) caused by nonobstructive hypertrophic cardiomyopathy (mean age, 55±0.26 years) were randomized to perhexiline 100 mg (n=24) or placebo (n=22). Myocardial ratio of phosphocreatine to adenosine triphosphate, an established marker of cardiac energetic status, as measured by 31 P magnetic resonance spectroscopy, left ventricular diastolic filling (heart rate normalized time to peak filling) at rest and during exercise using radionuclide ventriculography, peak V̇o 2 , symptoms, quality of life, and serum metabolites were assessed at baseline and study end (4.6±1.8 months). Perhexiline improved myocardial ratios of phosphocreatine to adenosine triphosphate (from 1.27±0.02 to 1.73±0.02 versus 1.29±0.01 to 1.23±0.01; P =0.003) and normalized the abnormal prolongation of heart rate normalized time to peak filling between rest and exercise (0.11±0.008 to −0.01±0.005 versus 0.15±0.007 to 0.11±0.008 second; P =0.03). These changes were accompanied by an improvement in primary end point (peak V̇ o 2 ) (22.2±0.2 to 24.3±0.2 versus 23.6±0.3 to 22.3±0.2 mL · kg −1 · min −1 ; P =0.003) and New York Heart Association class ( P <0.001) (all P values ANCOVA, perhexiline versus placebo). Conclusions—: In symptomatic hypertrophic cardiomyopathy, perhexiline, a modulator of substrate metabolism, ameliorates cardiac energetic impairment, corrects diastolic dysfunction, and increases exercise capacity. This study supports the hypothesis that energy deficiency contributes to the pathophysiology and provides a rationale for further consideration of metabolic therapies in hypertrophic cardiomyopathy. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00500552.